TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3.
TEM-89 (CMT-3) is the first complex mutant beta-lactamase produced by a clinical strain of Proteus mirabilis (strain Pm 631). This new enzyme, which has a pI of 6.28, is derived from TEM-3 and has a single amino acid substitution also encountered in TEM-59 (inhibitor-resistant TEM beta-lactamase IRT-17): Ser-130 to Gly. TEM-89 hydrolyzed penicillins to the same extent that TEM-3 did but lost almost all hydrolytic activity for cephalosporins and, like TEM-59, was highly resistant to inhibitors.
Neuwirth
C
C
Laboratoire de Bactériologie, Hôpital Universitaire du Bocage, 21034 Dijon Cedex, France. catherine.neuwirth@chu-dijon.fr
Madec
S
S
Siebor
E
E
Pechinot
A
A
Duez
J M
JM
Pruneaux
M
M
Fouchereau-Peron
M
M
Kazmierczak
A
A
Labia
R
R
D019943:Amino Acid Substitution; D003227:Conjugation, Genetic; D004926:Escherichia coli / Q000235:genetics; D006801:Humans; D007525:Isoelectric Focusing; D007700:Kinetics; D008969:Molecular Sequence Data; D009154:Mutation / Q000235:genetics; D010957:Plasmids / Q000235:genetics; D011512:Proteus Infections / Q000382:microbiology*; D011513:Proteus mirabilis / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D001618:beta-Lactamases / Q000235:genetics* / Q000378:metabolism*
C445689:TEM-89 beta-lactamase; D001618:beta-Lactamases